Zhengang Yuan

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

NAT2: A Novel Target in Intrahepatic Cholangiocarcinoma and its Role in Modulating Tumor Behavior.

NAT2: A Novel Target in Intrahepatic Cholangiocarcinoma and its Role in Modulating Tumor Behavior.

Journal: Clinical Medicine Insights. Oncology

Published: January 14, 2025

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

Journal: Liver cancer

Published: November 04, 2024

Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis.

Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis.

Journal: Frontiers in oncology

Published: August 19, 2024

A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021.

A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021.

Journal: Cancer innovation

Published: February 26, 2024

Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report.

Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report.

Journal: The Journal of international medical research

Published: November 02, 2023

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.

Journal: Cancer science

Published: September 30, 2023

Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor.

Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor.

Journal: Liver cancer

Published: July 28, 2022

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.

Journal: Frontiers in immunology

Published: October 22, 2021

Prognosis of Advanced Cholangiocarcinoma in the Palliative Care Setting: A Series of 201 Cases.

Prognosis of Advanced Cholangiocarcinoma in the Palliative Care Setting: A Series of 201 Cases.

Journal: Alternative therapies in health and medicine

Published: October 15, 2021

A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.

A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.

Journal: Molecular medicine reports

Published: September 18, 2019

Effects of knockout of lincRNA-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells.

Effects of knockout of lincRNA-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells.

Journal: Oncology letters

Published: March 28, 2018

Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis.

Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis.

Journal: Journal of Cancer

Published: August 07, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026